Cipla News and Updates

Name: Latest research reports of Cipla Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 3
Author: BOB Capital Markets Ltd.

Keep track of all breaking news on Cipla from all sources in a single place.

Cipla Ltd.

14 May 2026

1399.20

-0.19%

Pace of new product launches, filings key for Cipla's future growth

Business Standard

Strong India and Africa growth partially offset weakness in North America as Cipla focuses on respiratory launches and regulatory filings

BOB Capital Markets Ltd. decreased Hold price target of Cipla Ltd. to 1378.0 on 14 May, 2026.

Broker's call: Cipla (Buy)

Business Line | 14 May 2026 8 more

Cipla Ltd.

14 May 2026

1399.20

-0.19%

Cipla (HOLD): Mixed Earnings; exciting set of new products awaited

Hold: Cipla Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/PAT reported 1%/11%30% below estimates. Gross Margin reported 360 bps above; EBITDA Margin 176 bps below estimates

Cipla Ltd. has an average target of 1553.22 from 9 brokers.

Cipla Ltd.

14 May 2026

1399.20

-0.19%

Cipla (CIPLA IN) Q4FY26 Result Update Weak US revenues, timely launches will be key Accumulate

Accumulate: Cipla Ltd.

Target

Prabhudas Lilladhar

Muted US sales: CIPLA's Q4FY26 revenues declined 3% YoY to INR 65.4bn, below our estimates. Domestic formulation reported strong growth of 15% YoY. Key therapies such as Respiratory, Urology, Anti diabetic and Cardiac outpaced the market. US sales contribution from gRevlimid and supply issues in gLanreotide. One Africa business reported growth of 21% YoY; whereas EM + EU markets were down 8% YoY. Healthy GMs, EBITDA miss: GMs stood at 66%, down 185bps YoY but up 280bps QoQ. CIPLA reported EBITDA of INR 9.5bn; down 38% YoY; 7% below our estimates. OPM up 19% YoY and 3% QoQ. Ex R&D cost other expenses were up 6% YoY. Resultant PAT...

BOB Capital Markets Ltd. decreased Hold price target of Cipla Ltd. to 1378.0 on 14 May, 2026.

Cipla Ltd.

14 May 2026

1399.20

-0.19%

Cipla Ltd.

Buy: Cipla Ltd.

Target

ICICI Direct

The revenues were largely in line except US where intensity was tad higher which was offset by higher growth in other geographies. The management is confident of better performance from India and US in the ensuing year with better performance in second half. FY26 was year of some consolidation mainly due to genericization of gRevlimid and problems in some of its Key Products in US geographies. Going forward, the management momentum to really accelerate in the US from H2FY27 with an aspiration to reach US$ 1 billion annual revenue run rate by exit quarter...

Cipla Ltd. is trading above its 100 day SMA of 1338.2

Cipla Ltd.

13 May 2026

1399.20

-0.19%

Cipla Results Earnings Call for Q4FY26 & Full Year

Conference Call with Cipla Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

audio

Cipla Ltd.

13 May 2026

1399.20

-0.19%

to see Rapid results content

Cipla Ltd.

12 May 2026

1399.20

-0.19%

Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here

Business Standard

Cipla's March 2026 quarter revenue is expected to decline marginally to 6,665 crore as compared to 6,730 crore in the year-ago period

Cipla Ltd. has an average target of 1553.22 from 9 brokers.

Cipla Ltd.

27 Apr 2026

1399.20

-0.19%

Cohance Lifesciences shares zoom 20% to hit upper circuit; here's why

Business Standard

Cohance Lifesciences share price today: Cohance Lifesciences, a contract development and manufacturing organisation, has appointed Cipla's ex-CEO Umang Vohra as its executive chairman and group CEO.

Cipla Ltd. has an average target of 1553.22 from 9 brokers.

Cohance Lifesciences appoints former Cipla chief Umang Vohra as Executive Chairman, Group CEO

Business Line | 27 Apr 2026

Cipla Ltd.

24 Apr 2026

1399.20

-0.19%

Cipla gains US FDA nod for gVentolin; analysts see $100 mn sales potential

Business Standard

Cipla has received the US FDA's approval for generic Ventolin inhaler. Analysts see $100-million sales potential from the drug, which could aid US business outlook

Number of FII/FPI investors decreased from 1052 to 964 in Mar 2026 qtr

Cipla Ltd.

24 Apr 2026, 12:00AM

1399.20

-0.19%

Launches to address concern on US growth; valuation attractive

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Cipla’s recent product approval of gOfev and gVentolin from the USFDA is likely to start allaying concerns arising on its US growth post the discontinuation of Lanreotide, loss of exclusivity in gRevlimid and regulatory issues at key plants in India.

BOB Capital Markets Ltd. decreased Hold price target of Cipla Ltd. to 1378.0 on 14 May, 2026.

Is Cipla Ltd. worth buying?

650 Votes:

Buy 75.85%

Sell 13.54%

Hold 10.62%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf